ArticleJournal for immunotherapy of cancer2019

CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.

Reyes Gonzalez-Exposito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.